Results 31 to 40 of about 169,757 (284)

Chronic lymphocytic leukemia developing in a case of chronic myelogenous leukemia - accelerated phase: A rare case with review of the literature

Indian Journal of Pathology and Microbiology, 2013
Chronic myelogenous leukemia (CML) and chronic lymphocytic leukemia (CLL) are two different and common hematological neoplasms. Their coexistence is rare, especially CLL developing in a patient of CML. Till date, only a few cases are reported and all had
Narender Kumar, Jasmina Ahluwalia, Pankaj Malhotra, Man Updesh Singh Sachdeva   +3 more
doaj   +1 more source

Eradication of chronic myeloid leukemia stem cells: a novel mathematical model predicts no therapeutic benefit of adding G-CSF to imatinib [PDF]

, 2009
Imatinib mesylate induces complete cytogenetic responses in patients with chronic myeloid leukemia (CML), yet many patients have detectable BCR-ABL transcripts in peripheral blood even after prolonged therapy.
A Foudi, A Gothot, A Strife, A Wilson, AHG Hamilton, AR Oller, Bayard Clarkson, BJ Druker, C Cobaleda, C Roche-Lestienne, CH Jamieson, Christophe Fraser, CL Sawyers, D Dingli, E Passegue, F Arai, F Michor, F Michor, F Michor, Franziska Michor, GB Bradford, H Glimm, HG Jorgensen, I Roeder, J Cashman, J Cortes, Jasmine Foo, JC Wang, JD Rowley, JF Apperley, KJ Hope, KW Orford, L Ponchio, M Holtz, Mark W. Drummond, ME Gorre, MJ Mauro, MW Drummond, N Uchida, NL Komarova, NL Komarova, NP Shah, P Rousselot, PS Kim, S Branford, S Branford, S Merante, SM Graham, T Higashi, T Holyoake, T Lapidot, T Reya, Tessa Holyoake, TL Holyoake, W Ghanima, WR Bruce, Y Wang   +56 more
core   +4 more sources

Targeting methyltransferase PRMT5 eliminates leukemia stem cells in chronic myelogenous leukemia.

Journal of Clinical Investigation, 2016
Imatinib-insensitive leukemia stem cells (LSCs) are believed to be responsible for resistance to BCR-ABL tyrosine kinase inhibitors and relapse of chronic myelogenous leukemia (CML). Identifying therapeutic targets to eradicate CML LSCs may be a strategy
Yanli Jin, Jingfeng Zhou, Fang Xu, Bei Jin, L. Cui, Yun Wang, X. Du, Juan Li, Peng Li, R. Ren, Jingxuan Pan   +10 more
semanticscholar   +1 more source

MTSS1 is a critical epigenetically regulated tumor suppressor in CML [PDF]

, 2015
Chronic myeloid leukemia (CML) is driven by malignant stem cells that can persist despite therapy. We have identified Metastasis suppressor 1 (Mtss1/MIM) to be downregulated in hematopoietic stem and progenitor cells from leukemic transgenic SCLtTA/Bcr ...
Braunschweig, T., Brümmendorf, T. H., Chatain, N., Copland, M., Costa, I. G., Gusmao, E. G., Haenzelmann, S., Hamilton, A., Helgason, G.V., Herrmann, O., Holyoake, T. L., Kintsler, S., Koschmieder, S., Li, S., Merle Reher, M., Müller-Tidow, C., Schemionek, M., Schubert, C., Schwab, A.   +18 more
core   +1 more source

Excellent outcomes of 2G-TKI therapy after imatinib failure in chronic phase CML patients [PDF]

, 2018
open25noSecond-generation tyrosine kinase inhibitors (2G-TKIs) dasatinib and nilotinib produced historical rates of about 50% complete cytogenetic response (CCyR) and about 40% major molecular response (MMR) in chronic myeloid leukaemia (CML) patients ...

core   +1 more source

Chronic Myelogenous Leukemia- Initiating Cells Require Polycomb Group Protein EZH2.

Cancer Discovery, 2016
Tyrosine kinase inhibitors (TKI) have revolutionized chronic myelogenous leukemia (CML) management. Disease eradication, however, is hampered by innate resistance of leukemia-initiating cells (LIC) to TKI-induced killing, which also provides the basis ...
Huafeng Xie, Cong Peng, Jialiang Huang, Bin E. Li, Woojin Kim, Elenoe C Smith, Y. Fujiwara, J. Qi, G. Cheloni, P. Das, M. Nguyen, Shaoguang Li, J. Bradner, S. Orkin   +13 more
semanticscholar   +1 more source

Computational and mechanistic studies on the effect of galactoxyloglucan: Imatinib nanoconjugate in imatinib resistant K562 cells

Tumor Biology, 2017
Imatinib mesylate, a BCR/ABL fusion protein inhibitor, is the first-line treatment against chronic myelogenous leukemia. In spite of its advantageous viewpoints, imatinib still has genuine impediments like undesirable side effects and tumor resistance ...
Alphy Rose James, BS Unnikrishnan, R Priya, Manu M Joseph, TK Manojkumar, K Raveendran Pillai, R Shiji, GU Preethi, P Kusumakumary, TT Sreelekha   +9 more
doaj   +1 more source

Assembling defenses against therapy-resistant leukemic stem cells: Bcl6 joins the ranks [PDF]

, 2011
The resistance of leukemic stem cells in response to targeted therapies such as tyrosine kinase inhibitors (TKIs) relies on the cooperative activity of multiple signaling pathways and molecules, including TGFβ, AKT, and FOXO transcription factors ...
Austin, Bernardi, Bhatia, Brunet, Carayol, Chen, Chen, Druker, Duy, Fernández de Mattos, Francesca Pellicano, Graham, Hurtz, Ilaria, Ito, Komatsu, Lee, Mahon, Naka, Neubauer, Neviani, Neviani, Peng, Rowley, Samanta, Stambolic, Tessa L. Holyoake, Tothova, Xie, Yilmaz, Zhou   +30 more
core   +2 more sources

Heterogeneity of leukemia-initiating capacity of chronic myelogenous leukemia stem cells.

Journal of Clinical Investigation, 2016
Chronic myelogenous leukemia (CML) results from transformation of a long-term hematopoietic stem cell (LTHSC) by expression of the BCR-ABL fusion gene.
Bin Zhang, Ling Li, Yinwei Ho, Min Li, G. Marcucci, W. Tong, R. Bhatia   +6 more
semanticscholar   +1 more source

Chloroma of the testis in a patient with a history of acute myeloid leukemia

Journal of Research in Medical Sciences, 2017
Chloroma, or granulocytic sarcoma, is a rare extramedullary solid hematologic cancer, found concomitant with acute myeloid leukemia. It is infrequently associated with other myeloproliferative disorders or chronic myelogenous leukemia.
Mohammad Hossein Sanei, Matin Shariati
doaj   +1 more source